文献速递心力衰竭与心肌病

C反应蛋白与心血管疾病患者新发心力衰竭风险

C-Reactive Protein and Risk of Incident Heart Failure in Patients With Cardiovascular Disease.
PubMed 文献 · J Am Coll Cardiol · 2023-01-01

本研究基于UCC-SMART前瞻性队列中8089例已确诊心血管疾病但无心力衰竭的患者,评估基线C反应蛋白(CRP)与新发心力衰竭的关联。中位随访9.7年期间共观察到810例新发心力衰竭,校正-established风险因素后,CRP每升高1 mg/L与心衰风险增加10%独立相关,最高与最低四分位组风险比为2.22,且该关联在射血分数降低和保留的心衰中均显著。

要点

  • 在已确诊心血管疾病患者中,基线CRP是新发心力衰竭的独立风险标志物。
  • CRP每升高1 mg/L,新发心衰风险增加10%(HR 1.10,95%CI 1.07-1.13)。
  • 最高vs最低CRP四分位组新发心衰风险比为2.22(95%CI 1.76-2.79)。

核心结论

  • 在已确诊心血管疾病患者中,CRP是新发心力衰竭的独立风险标志物。
  • 该数据支持正在进行的评估抗炎药物能否减轻心衰负担的试验。

研究设计与样本

  • 前瞻性UCC-SMART队列研究,纳入已确诊心血管疾病但无 prevalent 心衰的患者8089例。
  • 新发心衰定义为首次因心衰住院,采用Cox比例风险模型校正已确立风险因素。

主要发现

  • 中位随访9.7年(IQR 5.4-14.1年)期间观察到810例新发心衰,发病率为1.01/100人年。
  • CRP每升高1 mg/L,新发心衰风险比为1.10(95%CI 1.07-1.13)。
  • 最高与最低CRP四分位组相比,新发心衰风险比为2.22(95%CI 1.76-2.79)。
  • 射血分数降低心衰风险比为1.09(95%CI 1.04-1.14),射血分数保留心衰风险比为1.12(95%CI 1.07-1.18),组间差异P=0.137。
  • 额外校正药物使用和期间心肌梗死未减弱关联,且CRP测量后15年以上关联仍一致。

临床怎么用

  • 对已确诊心血管疾病患者,可考虑检测基线CRP以辅助识别新发心衰高风险个体。
  • CRP升高提示系统性炎症可能参与心衰发生,支持抗炎治疗探索。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with established cardiovascular disease (CVD) are at high risk of incident heart failure (HF), which may in part reflect the impact of systemic inflammation. OBJECTIVES: The goal of this study was to determine the association between C-reactive protein (CRP) and incident HF in patients with established CVD. METHODS: Patients from the prospective UCC-SMART (Utrecht Cardiovascular Cohort-Second Manifestations of ARTerial disease) cohort with established CVD, but without prevalent HF were included (n = 8,089). Incident HF was defined as a first hospitalization for HF. The association between baseline CRP and incident HF was assessed using Cox proportional hazards models adjusted for established risk factors (ie, age, sex, myocardial infarction, smoking, diabetes mellitus, body mass index, blood pressure, cholesterol, and kidney function). RESULTS: During a median follow-up of 9.7 years (IQR 5.4-14.1 years), 810 incident HF cases were observed (incidence rate 1.01/100 person-years). Higher CRP was independently associated with an increased risk of incident HF: HR per 1 mg/L: 1.10 (95% CI: 1.07-1.13), and for last vs first CRP quartile: 2.22 (95% CI: 1.76-2.79). The association was significant for both HF with reduced (HR: 1.09; 95% CI: 1.04-1.14) and preserved ejection fraction (HR: 1.12; 95% CI: 1.07-1.18) (P for difference = 0.137). Additional adjustment for medication use and interim myocardial infarction did not attenuate the association, and the association remained consistent beyond 15 years after the CRP measurement. CONCLUSIONS: In patients with established CVD, CRP is an independent risk marker of incident HF. These data support ongoing trial efforts to assess whether anti-inflammatory agents can reduce the burden of HF.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Burger, Koudstaal, Mosterd, et al. C-Reactive Protein and Risk of Incident Heart Failure in Patients With Cardiovascular Disease. J Am Coll Cardiol. 2023. PMID: 37495278. doi:10.1016/j.jacc.2023.05.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。